What is being talked about, taught, and shared right now in the transthyretin amyloidosis space. This page brings together key moments and opportunities so our community can stay informed and show up prepared.
What’s Happening in ATTR.
Community conversations, webinars, and programs happening across the transthyretin amyloidosis space. These events are hosted by trusted organizations and shared here for awareness.
Upcoming Events
Alnylam Patient Event
ARC Talks
Amvuttra Patient Education Event(s)
ARC V122I Webinar
This educational video from the Heart Failure Society of America provides a clear overview of ATTR amyloidosis, including how it affects the body, common symptoms, and why early recognition matters.
Designed for patients and caregivers, it breaks down complex information into something more understandable and accessible. It also helps connect the dots between symptoms, diagnosis, and current treatment approaches.
HFSA continues to play an important role in advancing education, awareness, and care in heart failure and amyloidosis, helping both clinicians and communities better understand this condition.
What We’re Learning Over Time: New ATTR Data to be at ACC 2026
BridgeBio to present new data at ACC 2026 in New Orleans on its ATTR cardiomyopathy treatment, acoramidis. The update includes long-term results from its Phase 3 trial extension, offering a closer look at how patients are doing over time.
The data focused on outcomes like survival, disease stability, and quality of life, along with insights into how biomarkers may help track response to treatment. There was also growing interest in how these therapies perform outside of clinical trials, in real-world settings.
Overall, the findings reflect a continued shift toward understanding not just if treatments work, but how they hold up over time.
In the News
What Experts Are Watching in ATTR at ACC 2026
In this ACC 2026 preview, Dr. Kevin Alexander shares what he is most looking forward to in new ATTR cardiomyopathy research. He highlights upcoming data from major clinical trials, including deeper analysis of how patients are responding to treatment over time and what certain biomarkers may tell us about disease progression.
He also points to the importance of real-world data, looking at how currently available treatments are working outside of clinical trials. In addition, there is growing focus on imaging and how it can help doctors monitor patients more closely and guide treatment decisions.
Targeting the Buildup: New ATTR Approaches Continue to Evolve
A UK-based biotech company, Immutrin, has raised £65 million ($87 million) to develop a new type of treatment for ATTR amyloidosis. Unlike current therapies that focus on slowing the disease, this approach is designed to help clear existing amyloid buildup from the body. If successful, it could represent a meaningful step forward by targeting the underlying deposits that affect organs like the heart.